CSV November 24, 2022 through November 24, 2024 All Errata for USP–NF How to use

×

How to Use

- **Searching:** Type keyword in search field at top of page. Search by all or part of a monograph title. For searches using multiple criteria, you will find items that match each of the specified criteria unless quotation marks are used.
    - For example, a search on Aminosalicylic Acid Tablets will result in anything that contains “Aminosalicyclic” OR “Acid” OR “Tablets”
    - A search for “Aminosalicylic Acid Tablets” will result in anything that specifically contains “Aminosalicylic Acid Tablets”
- **Sorting:** Click on any column header title to sort alphabetically or chronologically in ascending or descending order. Note: the page load column is sorted alphabetically so that a number is ordered by first digit vs. by the actual number; thus, numbers will not always be in order.
    - For example, page 2178 will come before page 74 on a page sort.
- **Downloading:** You can download the Errata table in Comma-separated Value (.csv). The download will include the Errata that you have filtered on.
- **Importing:**You will need to import the file into Excel or Open Office with UTF-8 encoding, as opposed to simply opening it. To import, open Excel or Open Office and select import from the File drop-down. Depending on the version you are using, you should be presented with import formatting options to include UTF-8 as one of the first steps. Importing via UTF-8 should eliminate odd character conversions.

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
SALIX	INTRODUCTIO	*USP42–NF37*	5185	25-Jan-2019	1-Feb-2019	*NA*	*NA*	Delete

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
SPECIES BARK	N							(This monograph is postponed indefinitely.)
SALIX SPECIES BARK POWDER	ADDITIONAL REQUIREMENTS	*USP42–NF37*	5189	25-Jan-2019	1-Feb-2019	*NA*	*NA*	In *Labeling*: Change The label states the Latin binomial(s) of one or several *Salix* species included in the article. to: The label states the Latin binomial(s) of one or several *Salix* species included in the article. Dosage forms prepared with this article should bear the following statement: Not for use in children, women who are pregnant or nursing, or by

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								persons with known sensitivity to aspirin. AND In *USP Reference Standards* <*11*>: Delete (This monograph is postponed indefinitely.)
SALMETEROL INHALATION POWDER	ASSAY/ *Procedure/Analysis*	*First Supplement to USP41–NF36*	Online	25-Jan-2019	1-Feb-2019	*NA*	*NA*	In the definition list: Change M_{r1} = molecular weight of salmeterol free base, 415.75 to: M_{r1} = molecular weight of salmeterol free base, 415.57
SALIX SPECIES BARK DRY EXTRACT	ADDITIONAL REQUIREMENTS	*USP42–NF37*	5187	25-Jan-2019	1-Feb-2019	*NA*	*NA*	In *Labeling*: Change It meets the labeling requirements of *Botanical Extracts* <*565*>.

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								to: It meets the labeling requirements of *Botanical Extracts <565>*. Dosage forms prepared with this article should bear the following statement: Not for use in children, women who are pregnant or nursing, or by persons with known sensitivity to aspirin. AND In *USP Reference Standards <11>* : Delete (This monograph is postponed indefinitely.)
BENZETHONIUM		*First*	8297	25-Jan-2019	1-Feb-2019	*NA*	*NA*	In *Total*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
M CHLORIDE	PUR ITIES/*Organic Impuri ties/Acceptance criteria*	*Supplement to USP41–NF36*						*impurities*: Change 1.0% to: NMT 1.0%
SALIX SPECIES BARK	ADDITIONAL R EQUIREMENT S	*USP42–NF37*	5185	25-Jan-2019	1-Feb-2019	*NA*	*NA*	In *Labeling*: Change The label states the Latin binomial(s) of one or several *Salix* species included in the article. to: The label states the Latin binomial(s) of one or several *Salix* species included in the article. Dosage forms prepared with this article should bear the following statement: Not for use in children, women who are pregnant or

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								nursing, or by persons with known sensitivity to aspirin. AND In *USP Reference Standards* <*11*>: Delete (This monograph is postponed indefinitely.)
HOMATROPINE HYDROBROMIDE	*Limit of tropine*	*USP41–NF36*	2038	28-Dec-2018	1-Jan-2019	*NA*	*NA*	In *Tropine reference solution*: Change 0.4 mg per mL. to: 0.4 mg per mL in *Diluent*.
TRIAZOLAM TABLETS	*Uniformity of dosage units <905>*	*USP41–NF36*	4202	28-Dec-2018	1-Jan-2019	*NA*	*NA*	In *Mobile phase* and *Chromatographic system*: Change Proceed as directed in the *Assay* under *Triazolam*.

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								to: Proceed as directed in the *Assay*. AND In *Procedure*: Change Proceed as directed for *Procedure* in the *Assay* under *Triazolam*. to: Proceed as directed in the *Assay*.
PANTOPRAZOLE SODIUM	IMPURITIES/*Organic Impurities*/*Test 2*/ *Chromatographic system*	*First Supplement to USP41–NF36*	8392	28-Dec-2018	1-Jan-2019	*NA*	*NA*	In *Column*: Change 4.6-mm x 12.5-cm; 5-?m packing L1 to: 4-mm x 12.5-cm; 5-?m packing L1
METACRESOL	IDENTIFICATION/*B.*	*USP41–NF36*	2605	28-Dec-2018	1-Jan-2019	*NA*	*NA*	Change The retention time of the major peak of the *Sample solution*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								corresponds to that of the *Standard solution*, as obtained in the *Assay*. to: The retention time of the metacresol peak of the *Sample solution* corresponds to that of the *Standard solution*, as obtained in the *Assay*.
VITAMIN A	ADDITIONAL REQUIREMENTS	*USP41–NF36*	4327	28-Dec-2018	1-Jan-2019	*NA*	*NA*	Change Delete the following ?•*USP Reference Standards <11>* USP Retinyl Acetate RS USP Retinyl Palmitate RS ?(CN 1-May-2018) to: •*USP*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Reference Standards <11> USP Retinyl Acetate RS USP Retinyl Palmitate RS
ESOMEPRAZOLE MAGNESIUM DELAYED-RELEASE CAPSULES	PERFORMANCE TESTS/ *Dissolution <11>/Test 3/Buffer stage*	*Revision Bulletin (Official March 01, 2018)*	Online	28-Dec-2018	1-Jan-2019	*NA*	*NA*	In the *Standard solution*: Change 0.25 M sodium hydroxide, to: 0.25 N sodium hydroxide, AND In the *Sample solution*: Change 0.25sodium hydroxide, to: 0.25 N sodium hydroxide,
TELMISARTAN AND HYDROCHLOROTHIAZIDE TABLETS	PERFORMANCE TESTS/ *Dissolution <711>/Test 1/ Chromatographic system*	*Revision Bulletin (Official February 01, 2018)*	Online	28-Dec-2018	1-Jan-2019	*NA*	*NA*	In *Flow rate*: Change The flow rate goes back to 0.6 mL to: The flow rate goes back to

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
OLEYL OLEATE	CHEMICAL INFORMATION	*USP41–NF36*	5471	28-Dec-2018	1-Jan-2019	*NA*	*NA*	0.6 mL/min Change 532.92 to: 532.94
GLUTARAL CONCENTRATE	ASSAY/ *Procedure*	*USP41–NF36*	1960	30-Nov-2018	1-Dec-2018	*USP43–NF38*	*USP42–NF37*	In the variable definition list in *Analysis*: Change *W* = weight of Concentrate taken (g) to: *W* = nominal weight of glutaral taken (g)
AMLODIPINE AND ATORVASTATIN TABLETS	ASSAY/ *Procedure*	*First Supplement to USP41–NF36*	8270	30-Nov-2018	1-Dec-2018	*USP43–NF38*	*USP42–NF37*	In the second Calculate statement in *Analysis*: Change ($C_{33}H_{34}FN_2O_5$) to: ($C_{33}H_{35}FN_2O_5$)
OXYBUTYNIN CHLORIDE EXTENDED-RELEASE TABLETS	PERFORMANCE TESTS/ *Dissolution <711>/Test 8*	*Revision Bulletin (Official April 01, 2018)*	Online	30-Nov-2018	1-Dec-2018	*USP43–NF38*	*USP42–NF37*	In the variable definition list in *Analysis*: Change C_S = concentration of

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								oxybutynin chloride in the *Standard solution* (mg/mL) to: C_S = concentration of USP Oxybutynin Chloride RS in the *Standard solution* (mg/mL)
CUPRIC SULFATE INJECTION	*Assay*	*USP41–NF36*	1112	30-Nov-2018	1-Dec-2018	*USP43–NF38*	*USP42–NF37*	Line 8 of *Assay preparation*: Change to bring the total sodium content of this flask to 13.5 mg. to: to bring the total sodium chloride content of this flask to 13.5 mg.
PANTOPRAZOLE SODIUM DELAYED-RELEASE	PERFORMANCE TESTS/ *Dissolution Test*	*USP41–NF36*	3157	30-Nov-2018	1-Dec-2018	*USP43–NF38*	*USP42–NF37*	In the *Analysis*: Change Result = (r_U/r_S)

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
TABLETS	*1*							× C_S × (M_{r1}/M_{r2}) × V × (100/L) to: Result = (r_U/r_S) × C_S × (M_{r1}/M_{r2}) × V × (100/L) × D AND In the variable definition list in *Analysis*: Add D = dilution factor for the *Sample solution*, 2
NAPROXEN SODIUM TABLETS	IM PURITIES/*Organic Impurities*	*First Supplement to USP41–NF36*	8363	30-Nov-2018	1-Dec-2018	*USP43–NF38*	*USP42–NF37*	In the *System suitability solution*: Change 0.5 mg/mL of USP Naproxen Sodium RS and 0.5 µg/mL of USP Naproxen Related Compound A RS in *Diluent*, from *Standard stock solution 1* and *Standard stock solution 2*,

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								respectively to: 0.5 µg/mL of USP Naproxen Related Compound A RS from *Standard stock solution 2* and 0.5 mg/mL of USP Naproxen Sodium RS in *Diluent*
OXYBUTYNIN CHLORIDE EXTENDED-RELEASE TABLETS	IMPURITIES/*Organic Impurities*	*Revision Bulletin (Official April 01, 2018)*	Online	30-Nov-2018	1-Dec-2018	*USP43–NF38*	*USP42–NF37*	This erratum applies to the Revision Bulletin posted on www.uspnf.com only. In the variable definition list in *Analysis*: Change C_U = nominal concentration of the *Sample solution* (mg/mL) to: *C*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								U= nominal concentration of the *Sample solution* (mg/mL) [Note—Disregard any peak less than 0.1%.]
CUPRIC CHLORIDE	ASSAY/ *Procedure*	*USP41–NF36*	1109	30-Nov-2018	1-Dec-2018	*USP43–NF38*	*USP42–NF37*	Line 1 of *Analysis*: Change To the *Sample solution* to: To 50 mL of the *Sample solution*
AZEOTROPIC ISOPROPYL ALCOHOL	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*USP41–NF36*	2257	30-Nov-2018	1-Dec-2018	*USP43–NF38*	*USP42–NF37*	Line 1 of USP 2-Propanol System Suitability RS: Change It contains 0.1% of each of the following: ethyl ether, acetone, isopropyl alcohol, diisopropyl ether, 1-propanol, and 2-butanol.

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								to: It is a mixture of the following: ethyl ether (0.1%), acetone (0.1%), diisopropyl ether (0.1%), 1-propanol (0.1%), 2-butanol (0.1%), and isopropyl alcohol (99.5%).
AMLODIPINE AND ATORVASTATIN TABLETS	PERFORMANCE TESTS/ *Dissolution <711>*	*First Supplement to USP41–NF36*	8270	30-Nov-2018	1-Dec-2018	*USP43–NF38*	*USP42–NF37*	In the second Calculate statement in *Analysis*: Change ($C_{33}H_{34}FN_2O_5$) to: ($C_{33}H_{35}FN_2O_5$) AND In *Tolerances*: Change ($C_{33}H_{34}FN_2O_5$) to: ($C_{33}H_{35}FN_2O_5$)
LIDOCAINE	ASSAY/ *Procedure*	*First Supplement to USP41–NF36*	Online	30-Nov-2018	1-Dec-2018	*USP43–NF38*	*USP42–NF37*	This erratum applies to the new *USP-NF*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								ONLINE platform only. Line 2 of *Standard solution*: Change 1 N sodium hydroxide, to: 1 N hydrochloric acid, AND Line 2 of *Sample solution*: Change 1 N sodium hydroxide, to: 1 N hydrochloric acid,
ALLOPURINOL	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*USP41–NF36*	121	30-Nov-2018	1-Dec-2018	*USP43–NF38*	*USP42–NF37*	Line 3 of USP Allopurinol Related Compound A RS: Change $(C_5H_6N_4O)_2 \cdot H_2SO_4$ 350.32 to: $(C_4H_6N_4O)_2 \cdot H$

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								$^{2}SO_4$ 350.31

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
FLUTICASONE PROPIONATE INHALATION POWDER	IMPURITIES/*Organic Impurities/System suitability*	*USP41–NF36*	1836	30-Nov-2018	1-Dec-2018	*USP43–NF38*	*USP42–NF37*	In the *Tailing factor*: Change NLT 1.3 to: NMT 1.3
AMLODIPINE AND ATORVASTATIN TABLETS	DEFINITION	*First Supplement to USP41–NF36*	8270	30-Nov-2018	1-Dec-2018	*USP43–NF38*	*USP42–NF37*	Line 4: Change ($C_{33}H_{34}FN_2O_5$) to: ($C_{33}H_{35}FN_2O_5$)
OCTOCRYLENE	SPECIFIC TESTS/*Acidity*	*First Supplement to USP41–NF36*	8379	30-Nov-2018	1-Dec-2018	*USP43–NF38*	*USP42–NF37*	Line 1 of *Acceptance criteria*: Change NMT 0.18 mL of *Titrant* is required to: NMT 0.18 mL of *Titrant*/g is required
CUPRIC CHLORIDE INJECTION	ASSAY/*Procedure*	*USP41–NF36*	1111	30-Nov-2018	1-Dec-2018	*USP43–NF38*	*USP42–NF37*	Line 3 of *Sample solution*: Change to bring the total sodium content of this flask to 13.5 mg. to: to bring the total sodium chloride

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								content of this flask to 13.5 mg.
METOPROLOL TARTRATE	CHEMICAL INFORMATION	*USP41–NF36*	2712	30-Nov-2018	1-Dec-2018	*USP43–NF38*	*USP42–NF37*	Line 4: Change (±)-1-(Isopropylamino)-3-[*p*-(2-methoxyethyl)phenoxy]-2-propanol l-(+)-tartrate (2:1) (salt); 1-(Isopropylamino)-3-[*p*-(2-methoxyethyl)phenoxy]-2-propanol (2:1) *dextro*-tartrate salt to: (±)-1-(Isopropylamino)-3-[*p*-(2-methoxyethyl)phenoxy]-2-propanol (+)-tartrate (2:1) (salt); 1-(Isopropylamino)-3-[4-(2-methoxyethyl)phen

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								oxy]propan-2-ol L-tartrate
ACAMPROSATE CALCIUM	IMPURITIES/*Limit of Acamprosate Related Compound A*	*First Supplement to USP41–NF36*	8263	30-Nov-2018	1-Dec-2018	*USP43–NF38*	*USP42–NF37*	In the variable definition list in *Analysis*: Change C_S = concentration of USP Acamprosate Calcium Related Compound A RS in the *Standard solution* (µg/mL) to: C_S = concentration of USP Acamprosate Related Compound A RS in the *Standard solution* (µg/mL)
OXYBUTYNIN CHLORIDE EXTENDED-RELEASE TABLETS	ASSAY/*Procedure*	*Revision Bulletin (Official April 01, 2018)*	Online	30-Nov-2018	1-Dec-2018	*USP43–NF38*	*USP42–NF37*	This erratum applies to the Revision Bulletin posted on

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								www.uspnf.com only. In *System suitability*: Add [Note—The relative retention times for oxybutynin and oxybutynin related compound A are about 1.0 and 1.6, respectively.]
CIPROFLOXACIN AND DEXAMETHASONE OTIC SUSPENSION	IMPURITIES	*USP41–NF36*	951	30-Nov-2018	1-Dec-2018	*USP43–NF38*	*USP42–NF37*	In the variable definition list of *Ciprofloxacin Related Compounds/Analysis*: Change C_U = nominal concentration of ciprofloxacin in the Otic Suspension (mg/mL) to: C_U = nominal concentration of

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								ciprofloxacin in the *Sample solution* (mg/mL) AND In the variable definition list of *Dexamethasone Related Compounds/Analysis*: Change C_U = nominal concentration of dexamethasone in the Otic Suspension (mg/mL) to: C_U = nominal concentration of dexamethasone in the *Sample solution* (mg/mL)
GUAIFENESIN	IMPURITIES/*Organic Impurities*	*USP41–NF36*	2001	26-Oct-2018	1-Nov-2018	*USP43–NF38*	*Second Supplement to USP41–NF36*	In the equation in *Analysis*: Change Result = (r_U/r_S) × (1/*F*) × 100

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								to: Result = (r_U/r_S) × (C_S/C_U) × (1/F) × 100 AND Add to the variable list: C_S = concentration of guaifenesin in the *Diluted sample solution* C_U = concentration of guaifenesin in the *Sample solution*
WATER FOR INJECTION	ADDITIONAL REQUIREMENTS	*USP41–NF36*	4345	26-Oct-2018	1-Nov-2018	*USP43–NF38*	*Second Supplement to USP41–NF36*	Delete • *USP Reference Standards <11>* USP 1,4-Benzoquinone RS
PURIFIED WATER	ADDITIONAL REQUIREMENTS	*USP41–NF36*	4347	26-Oct-2018	1-Nov-2018	*USP43–NF38*	*Second Supplement to USP41–NF36*	Delete • *USP Reference Standards <11>* USP 1,4-Benzoquinone RS
AMOXICILLIN	IDENTIFICATION/*A.*	*First Supplement to*	Online	26-Oct-2018	1-Nov-2018	*USP43–NF38*	*Second Supplement to*	This erratum applies to the

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
		USP41–NF36					*USP41–NF36*	new *USP-NF* ONLINE platform only. Line 1: Change *Infrared Absorption <197>* to: *Infrared Absorption <197K>*
RIZATRIPTAN BENZOATE	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*USP41–NF36*	3662	26-Oct-2018	1-Nov-2018	*USP43–NF38*	*Second Supplement to USP41–NF36*	Line 6 of USP Rizatriptan Benzoate System Suitability Mixture RS: Change 269.34) to: 269.35)
STERILE WATER FOR INJECTION	ADDITIONAL REQUIREMENTS	*USP41–NF36*	4346	26-Oct-2018	1-Nov-2018	*USP43–NF38*	*Second Supplement to USP41–NF36*	Delete • *USP Reference Standards <11>* USP 1,4-Benzoquinone RS
ZOLMITRIPTAN TABLETS	IMPURITIES/*Organic Impurities*	*Revision Bulletin (Official November 01, 2017)*	Online	26-Oct-2018	1-Nov-2018	*USP43–NF38*	*Second Supplement to USP41–NF36*	Line 2 of *Analysis*: Change *Sample*:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Sample solution to: *Samples*: *Standard solution* and *Sample solution*
LEVODOPA	IMPURITIES/*Organic Impurities*	*USP41–NF36*	2392	26-Oct-2018	1-Nov-2018	*USP43–NF38*	*Second Supplement to USP41–NF36*	Footnote a of *Table 1*: Change 3-(3,4,6-Trihydroxyphenyl)alanine. to: 3-(3,4,6-Trihydroxyphenyl)alanine; also known as 3-(2,4,5-Trihydroxyphenyl)-L-alanine.
WATER FOR HEMODIALYSIS	ADDITIONAL REQUIREMENTS	*USP41–NF36*	4345	26-Oct-2018	1-Nov-2018	*USP43–NF38*	*Second Supplement to USP41–NF36*	Delete • *USP Reference Standards <11>* USP 1,4-Benzoquinone RS
STERILE PURIFIED WATER	ADDITIONAL REQUIREMENTS	*USP41–NF36*	4348	26-Oct-2018	1-Nov-2018	*USP43–NF38*	*Second Supplement to USP41–NF36*	Delete • *USP Reference Standards <11>* USP 1,4-Benzoquinone RS

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
DROSPIRENONE AND ETHINYL ESTRADIOL TABLETS	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*USP41–NF36*	1447	26-Oct-2018	1-Nov-2018	*USP43–NF38*	*Second Supplement to USP41–NF36*	Line 2 of USP Ethinyl Estradiol Related Compound B RS: Change 19-Nor-17?-pregna-1,3,5(10),9(11)-tetraen-20-yne-3,17-diol. $C_{20}H_{22}O_2$ 294.39 to: 19-Nor-17?-pregna-1,3,5(10),9(11)-tetraen-20-yne-3,17-diol monohydrate. $C_{20}H_{22}O_2 \cdot H_2O$ 312.40
VINORELBINE INJECTION	ASSAY/*Procedure*/*System suitability*/*Suitability requirements*	*USP41–NF36*	4326	26-Oct-2018	1-Nov-2018	*USP43–NF38*	*Second Supplement to USP41–NF36*	Line 1 of *Relative standard deviation*: Change NLT 2.0%, *Standard solution* to: NMT 2.0%, *Standard solution*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
STERILE WATER FOR IRRIGATION	ADDITIONAL REQUIREMENTS	*USP41–NF36*	4347	26-Oct-2018	1-Nov-2018	*USP43–NF38*	*Second Supplement to USP41–NF36*	Delete • *USP Reference Standards <11>* USP 1,4-Benzoquinone RS
RITONAVIR CAPSULES	PERFORMANCE TESTS/ *Dissolution <711>/Test 2*	*Revision Bulletin (Official April 01, 2018)*	Online	26-Oct-2018	1-Nov-2018	*USP43–NF38*	*Second Supplement to USP41–NF36*	Row 1 of Column 3 of *Table 1*: Change *Tolerances (Q)* to: *Tolerances* AND Row 3 of Column 3 of *Table 1*: Change NLT 80% to: NLT 80% (*Q*)
NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE ACETATE OPHTHALMIC SUSPENSION	*Assay for hydrocortisone acetate*	*USP41–NF36*	2904	26-Oct-2018	1-Nov-2018	*USP43–NF38*	*Second Supplement to USP41–NF36*	Line 1: Change Proceed with Ophthalmic Suspension as directed in the *Assay* under *Hydrocortisone Acetate Injectable Suspension*.

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								to: *Standard preparation*—Prepare as directed for *Assay for Steroids <351>*, *Standard Preparation*, using USP Hydrocortisone Acetate RS. *Assay preparation*—Transfer to a separator an accurately measured volume of Ophthalmic Suspension, equivalent to about 50 mg of hydrocortisone acetate, and dilute with water to about 15 mL. Extract with four 25-mL portions of chloroform,

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								filtering each portion through chloroform-washed cotton into a 250-mL volumetric flask. Add chloroform to volume, and mix. Pipet 10 mL of this solution into a 100-mL volumetric flask, add chloroform to volume, and mix. Pipet 10 mL of the resulting solution into a gl ass-stoppered, 50-mL conical flask, evaporate the chloroform on a steam bath just to dryness, cool, and dissolve the residue in 20.0 mL of alcohol. *Proce dure*—Proceed

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								as directed for *Assay for Steroids* <*351*>, *Procedure*. Calculate the quantity, in mg, of hydrocortisone acetate ($C_{23}H_{32}O_6$) in each mL of Ophthalmic Suspension taken by the formula: $5(C/V)(A_U/A_S)$ in which V is the volume, in mL, of Ophthalmic Suspension taken; and the other terms are defined therein.
STERILE WATER FOR INHALATION	ADDITIONAL REQUIREMENTS	*USP41–NF36*	4346	26-Oct-2018	1-Nov-2018	*USP43–NF38*	*Second Supplement to USP41–NF36*	Delete • *USP Reference Standards* <*11*> USP 1,4-Benzoquinone RS

Pagination

- First page « First
- Previous page ‹ Previous
- …
- Page 5
- Page 6
- Page 7
- Page 8
- Page 9
- Page 10
- Page 11
- Page 12
- Page 13
- …
- Next page Next ›
- Last page Last »